Hugel said it showcased new clinical findings for its botulinum toxin (BTX) product at the 25th International Master Course on Aging Science (IMCAS) World Congress, held in Paris, France, from Feb. 1 to 3.

The event, which is recognized as the world's largest conference on aesthetic plastic surgery, attracted approximately 18,000 industry professionals.

During a session titled "Updated and future aesthetic toxins," Hugel Co-CEO Moon Hyoung-jin spoke on new toxins from Asia. 

The presentation highlighted the efficacy and safety of LetibotulinumtoxinA, marketed as Letybo, in improving glabellar lines in Asian patients, demonstrating non-inferiority and high patient satisfaction compared to Onabotulinumtoxin A, the control group. 

A separate study on Korean patients for the treatment of masseter muscle hypertrophy showed significant efficacy across all doses, especially at doses above 48 units.

Additionally, Hugel introduced follow-up studies from the BLESS III clinical trial on patients in the U.S. and Europe, revealing that Letybo significantly improved the psychological well-being related to glabellar lines after four weeks, based on the Modified Skindex-16 GL-QoL Scale.

The findings suggest Letybo's effectiveness and safety in treating glabellar lines and masseter hypertrophy across various ethnic groups, as well as its significant psychological benefits.

During the convention, Hugel also introduced of a range of other aesthetic products, including hyaluronic acid (HA) fillers and surgical sutures.

Hugel's subsidiaries, the HA filler company Across and the suture manufacturer J World, also participated in the congress. Across’ HA fillers is already available in 34 countries including the top five European markets -- Germany, the U.K., France, Italy, and Spain.

J World's stressed that its suture is distinguished by a unique minimal-heated press molding sculpting process, address the weaknesses of traditional polydioxanone (PDO) sutures and offer enhanced efficacy. 

Following a successful launch in the Thailand market in June of the previous year, J World is set to target the European market aggressively this year. 

Both Moon and co-CEO Han Seon-ho expressed enthusiasm about showcasing the company's product excellence at the world's largest aesthetic surgery conference and emphasized the importance of networking with medical professionals from Europe, Asia, and America to enhance corporate value and expand global outreach.

[